Pooja M. Phull

Hematology Oncology
7650 River Road
Suite 200
North Bergen, NJ 7047.

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma.

Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma.

Journal: Leukemia & lymphoma
Published: August 11, 2026

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Journal: Current oncology (Toronto, Ont.)
Published: June 27, 2026

Using cell-free RNA to identify B- and T-cell clonality for diagnosis and monitoring of B- and T-cell neoplasms.

Using cell-free RNA to identify B- and T-cell clonality for diagnosis and monitoring of B- and T-cell neoplasms.

Journal: FEBS open bio
Published: June 07, 2026

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Journal: Cancers
Published: May 18, 2026

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.

Journal: Transplantation and cellular therapy
Published: March 11, 2026

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Journal: European journal of haematology
Published: January 09, 2026

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Journal: Leukemia & lymphoma
Published: December 02, 2025

Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.

Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.

Journal: Blood advances
Published: November 03, 2025

Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

Journal: Blood advances
Published: November 03, 2025

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.

Journal: Haematologica
Published: November 27, 2024

Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM).

Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM).

Journal: Journal of clinical medicine
Published: September 05, 2024

Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients.

Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients.

Journal: European journal of haematology
Published: August 02, 2024
Showing 1-12 of 24

Last Updated: 09/26/2026